Statin Intolerance: Some Practical Hints

Maciej Banach; Dimitri P Mikhailidis

doi:10.1016/j.ccl.2017.12.004

Statin Intolerance: Some Practical Hints

Cardiol Clin. 2018 May;36(2):225-231. doi: 10.1016/j.ccl.2017.12.004. Epub 2018 Feb 21.

Authors

Maciej Banach¹, Dimitri P Mikhailidis²

Affiliations

¹ Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz (MUL), 113 Zeromskiego Street, Lodz 90-549, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), 281/289 Rzgowska Street, Lodz 93-338, Poland; Cardiovascular Research Centre, University of Zielona Gora, 28 Zyty Street, Zielona Gora 65-046, Poland. Electronic address: maciejbanach@aol.co.uk.
² Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK.

PMID: 29609752
DOI: 10.1016/j.ccl.2017.12.004

Abstract

Statin intolerance is the inability to tolerate a dose of statin required to sufficiently reduce cardiovascular risk. With the five-step approach, more than 90% of these patients might be treated with statins. The principal approaches are to try not to discontinue statin therapy and to treat these patients as effectively as possible. New therapies with the proprotein convertase subtilisin-kexin type 9 inhibitors and bempedoic acid might be an effective response to these needs. In case of lack of achieved goal of the therapy nutraceuticals with confirmed low-density lipoprotein cholesterol reduction properties may be considered as a part of the lipid-lowering combination therapy.

Keywords: Adverse effects; Cardiovascular disease; Statin-associated muscle symptoms; Statins; Therapy.

Publication types

Review

MeSH terms

Cardiovascular Diseases / drug therapy*
Dose-Response Relationship, Drug
Drug Tolerance*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Risk Factors

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors